PE74799A1 - ANTIVIRAL COMBINATIONS - Google Patents

ANTIVIRAL COMBINATIONS

Info

Publication number
PE74799A1
PE74799A1 PE1998000375A PE00037598A PE74799A1 PE 74799 A1 PE74799 A1 PE 74799A1 PE 1998000375 A PE1998000375 A PE 1998000375A PE 00037598 A PE00037598 A PE 00037598A PE 74799 A1 PE74799 A1 PE 74799A1
Authority
PE
Peru
Prior art keywords
reverse transcriptase
inhibitors
composition
hiv protease
inhibitor
Prior art date
Application number
PE1998000375A
Other languages
Spanish (es)
Inventor
Clair Martha Heider St
David Walter Barry
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719883.2A external-priority patent/GB9719883D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE74799A1 publication Critical patent/PE74799A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

CARACTERIZADA PORQUE COMPRENDE (-)-(1S,4R)-4-[2-AMINO-6-(CICLOPROPILAMINO)-9H-PURIN-9-IL]-2-CICLOPENTEN-1-METANOL (1592U89) Y UNO O MAS INHIBIDORES DE TRANSCRIPTASA INVERSA NO NUCLEOSIDO EN PARTICULAR NEVIPARINA, LOVIRIDINA, DESLAVURIDINA, 2(S)-7-FLUORO-3,4-DIHIDRO-2-ETIL-3-OXO-1-(2H)-QUINOXALIN CARBOXILATO DE ISOPROPILO (HBY-1293) TAMBIEN LA COMPOSICION PUEDE CONTENER UN INHIBIDOR DE TRANSCRIPTASA INVERSA O UN INHIBIDOR DE PROTEASA DEL VIH. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA INFECCION POR VIH RESISTENTE A LOS INHIDORES DE LA TRANSCRIPTASA INVERSA, NUCLEOSIDOS O INHIBIDORES DE PROTEASA DEL VIHCHARACTERIZED BECAUSE IT INCLUDES (-) - (1S, 4R) -4- [2-AMINO-6- (CICLOPROPILAMINO) -9H-PURIN-9-IL] -2-CICLOPENTEN-1-METHANOL (1592U89) AND ONE OR MORE INHIBITORS OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE IN PARTICULAR NEVIPARINE, LOVIRIDINE, DESLAVURIDINE, 2 (S) -7-FLUORO-3,4-DIHIDRO-2-ETILL-3-OXO-1- (2H) -QUINOXALIN CARBOXYLATE ISOPROPYL (HBY-12 -93 ) THE COMPOSITION MAY ALSO CONTAIN A REVERSE TRANSCRIPTASE INHIBITOR OR AN HIV PROTEASE INHIBITOR. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF A HIV INFECTION RESISTANT TO INVERTERS OF REVERSE TRANSCRIPTASE, NUCLEOSIDES OR INHIBITORS OF HIV PROTEASE

PE1998000375A 1997-05-17 1998-05-14 ANTIVIRAL COMBINATIONS PE74799A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GBGB9719883.2A GB9719883D0 (en) 1997-09-19 1997-09-19 Antiviral combinations

Publications (1)

Publication Number Publication Date
PE74799A1 true PE74799A1 (en) 1999-08-13

Family

ID=26311543

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000375A PE74799A1 (en) 1997-05-17 1998-05-14 ANTIVIRAL COMBINATIONS

Country Status (12)

Country Link
EP (1) EP0979082A1 (en)
JP (1) JP2001525839A (en)
AR (1) AR012702A1 (en)
AU (1) AU7912398A (en)
BR (1) BR9809127A (en)
CA (1) CA2289655A1 (en)
CO (1) CO4950569A1 (en)
HR (1) HRP980264A2 (en)
MA (1) MA26496A1 (en)
NO (1) NO995620L (en)
PE (1) PE74799A1 (en)
WO (1) WO1998052570A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990030A2 (en) * 1998-02-17 1999-10-31 Michael B. Maurin Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
PE20000559A1 (en) * 1998-05-27 2000-07-05 Merck & Co Inc FORMULATION OF EFAVIRENZ COMPRESSED TABLETS
WO2013111147A1 (en) * 2011-12-19 2013-08-01 Hetero Research Foundation Extended release compositions of nevirapine
JP6391561B2 (en) * 2013-02-27 2018-09-19 国立大学法人京都大学 Pharmaceutical composition for preventing or treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc

Also Published As

Publication number Publication date
MA26496A1 (en) 2004-12-20
AU7912398A (en) 1998-12-11
CA2289655A1 (en) 1998-11-26
HRP980264A2 (en) 1999-02-28
JP2001525839A (en) 2001-12-11
NO995620D0 (en) 1999-11-16
WO1998052570A1 (en) 1998-11-26
AR012702A1 (en) 2000-11-08
BR9809127A (en) 2000-08-01
EP0979082A1 (en) 2000-02-16
CO4950569A1 (en) 2000-09-01
NO995620L (en) 2000-01-14

Similar Documents

Publication Publication Date Title
ES2174992T3 (en) INTERMEDIATE PRODUCTS FOR THE OBTAINING OF INHIBITING COMPOUNDS OF RETROVIRAL PROTEASES.
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
MX9403380A (en) HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS.
DK0656888T3 (en) Sulfonylalkanoylaminohydroxyethylaminosulfonamides useful as retroviral protease inhibitors
CL2004002061A1 (en) COMPOUNDS DERIVED FROM CONDENSED HETEROCICLES CONTAINING NITROGEN; PHARMACEUTICAL COMPOSITION; AND ITS USE AS AN ANTIVIRAL AGENT, INTEGRASA INHUBIDATOR AND AS AN ANTI-HIV AGENT.
ES2177868T3 (en) HYDROXYETHYLAMINOSULPHONAMIDS OF ALPHA- AND BETA-AMINO ACIDS AS INHIBITORS OF RETROVIRIC PROTEASES.
DK0656886T3 (en) N- (Alkanoylamino-2-hydroxypropyl) sulfonamides for use as inhibitors of retroviral proteases
DE69333378D1 (en) PHARMACEUTICAL COMPOSITIONS WITH INTERLEUKIN-1 INHIBITORS
NO20052159L (en) Substituted (thiazol-2-yl) amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes.
ES2174921T3 (en) HIV PROTEASE INHIBITORS.
AR009145A1 (en) GUANIDINYL HETERO-CYCLE COMPOUNTS USEFUL AS ALPHA-2 ADRENORECEPTOR AGONISTS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
PE74799A1 (en) ANTIVIRAL COMBINATIONS
NO993670L (en) Quinoxaline in triple combination with protease inhibitors and reverse transcriptase inhibitors as drugs for the treatment of AIDS
PA8461601A1 (en) ISOQUINOLINS
ES2103493T3 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY.
ES2164724T3 (en) USE OF AN ENZYME TO PREPARE AN AGENT FOR THE TREATMENT AND / OR PROFILAXIS OF COCCIDIOSIS.
AR049560A2 (en) CRYSTAL FORMS OF (2S, 3S, 5S) -2- (2,6-DIMETHYLPHENOXIACETILE) AMIN 3-HYDROXY-5- (2- (1-TETRAHYDROPIRIMID-2-ONIL) -3-METHYLBUTANOL) AMIN-1,6- DIFENILHEXANO (LOPINAVIR)
DK0669803T3 (en) Use of amidoamines in ophthalmic compositions
UY26329A1 (en) VITRONECTIN RECEPTOR ANTAGONISTS
PE20000020A1 (en) COMPOSITIONS FOR THE TREATMENT OF AIDS AND HIV INFECTION
DE69332904T2 (en) INHIBITION OF HIV INFECTION
ES2036697T3 (en) SPHERICAL CONTACT LENS FOR THE CORRECTION OF PRESBICIA.
DOP2002000449A (en) SODIUM SALT OF AN HIV INTEGRADASA INHIBITOR.
ATE293667T1 (en) CLEANING AGENTS CONTAINING SURFACTANTS WITH ENZYME INHIBITORS
PA8498601A1 (en) ANTI-COLOR COMPOSITION

Legal Events

Date Code Title Description
FC Refusal